SynthesisFrontiers in nutrition2025
Association of high consumption of soy products with the risk of cognitive impairment and major neurocognitive disorders: a systematic review and dose-response meta-analysis.
Synthesis in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Protein Consumption and Cognitive Health in Aging: Associations with Sarcopenia and Dietary Options, a Narrative Review.Nutrients · 2026Review
- Poststroke anxiety and depression: epidemiology, mechanisms, and management strategies.Frontiers in psychiatry · 2026Review
- Therapeutic Efficacy of Soy-Derived Bioactives: A Systematic Review of Nutritional Potency, Bioactive Therapeutics, and Clinical Biomarker Modulation.Foods (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: While soy products can potentially affect cognitive function through various mechanisms, the dose-response connection of high soy consumption with major neurocognitive disorder or cognitive impairment remains unclear. Methods: A comprehensive retrieval was performed on PubMed, Embase, Cochrane Library, and Web of Science databases up to September 2024, to identify prospective or cohort studies (without language restrictions) examining the link between high soy consumption and the likelihood of developing major neurocognitive disorder or cognitive impairment. Stata (V15) was employed for data analysis, and a restricted cubic spline (RCS) model was employed for examining the dose-response effect. Results: Six studies incorporating 68,691 participants were included. Elevated consumption of total soy products was markedly correlated to a reduced likelihood of developing major neurocognitive disorder [odds ratios (OR) = 0.92, 95% confidence intervals (95%CI): 0.84-0.99]. While an association with increased risk of cognitive impairment was observed, it was not statistically significant. The dose-response meta-analysis indicated that a 1-g per day increase in the consumption of soy and natto demonstrated a correlation with an 8 and 14% decrease in the likelihood of developing major neurocognitive disorder, respectively. Subgroup analysis suggested a more pronounced protective effect in individuals not experiencing stroke (OR = 0.66, 95%CI: 0.53-0.82). However, soy consumption showed a paradoxical association with the likelihood of developing cognitive impairment (OR = 1.20, 95%CI: 0.83-1.72). Risk data showed no significant association with cognitive impairment. Dose-response data further explained an inverse relationship between dose and risk of cognitive impairment, with higher doses associated with lower risk. Conclusion: Elevated consumption of diverse soy products exhibited a linear negative correlation with cognitive decline or major neurocognitive disorder; however, significant heterogeneity remained within both the overall analysis and multiple subgroup analyses. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, CRD42024508555.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.